Ardelyx Inc., a biopharmaceutical firm, has been making strides in discovering, developing, and selling medicines to address therapeutic areas in gastrointestinal and cardiorenal care both domestically and internationally. The company's top product candidate, tenapanor, has shown promise for treating patients with irritable bowel syndrome with constipation. Additionally, the firm is spearheading XPHOZAH in Phase III clinical trial for controlling serum phosphorus in adult patients with chronic kidney disease on dialysis or hyperphosphatemia. RDX013, a potassium secretagogue, is in development to treat elevated serum potassium, or hyperkalemia, which is a growing issue for those with kidney and heart disease. RDX020 seeks to address metabolic acidosis for adult patients, a severe electrolyte imbalance. Moreover, Ardelyx has teamed up with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics Inc. to develop and commercialize tenapanor in their specific territories. In 2008, the company changed its name to Ardelyx Inc., previously known as Nteryx Inc., after incorporating in 2007. The Waltham, Massachusetts-based company has emerged as a leader in the biopharmaceutical space.
Ardelyx Inc's ticker is ARDX
The company's shares trade on the NASDAQ stock exchange
They are based in Fremont, California
There are 51-200 employees working at Ardelyx Inc
It is http://www.ardelyx.com/
Ardelyx Inc is in the Healthcare sector
Ardelyx Inc is in the Biotechnology industry
The following five companies are Ardelyx Inc's industry peers: